The first approved drug for NF1‐related inoperable PN, selumetinib, a MEK inhibitor that has shown activity against several advanced cancers (Dombi et al., 2016; Mukhopadhyay et al., 2021). This evidence concerns the gene MAP2K7 and poikiloderma with neutropenia.